The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal

The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal

Abstract Background Oral semaglutide is a novel glucagon-like peptide-1 (GLP-1) analog that has been associated with improvements in glycated hemoglobin (HbA1c) and body weight versus sodium-glucose cotransporter-2 inhibitor empagliflozin and injectable GLP-1 receptor agonist dulaglutide in the PION...

Full description

Bibliographic Details
Main Authors: Samuel J. P. Malkin, Davide Carvalho, Catarina Costa, Vasco Conde, Barnaby Hunt
Format: Article
Language:English
Published: BMC 2022-02-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Costs and cost analysis
Cost-effectiveness
Diabetes mellitus
Dulaglutide
Empagliflozin
GLP-1 receptor agonist
Online Access:https://doi.org/10.1186/s13098-022-00801-4

Internet

https://doi.org/10.1186/s13098-022-00801-4

Similar Items